{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:14:37Z","timestamp":1760919277544,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.cld.2025.06.002","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:33:49Z","timestamp":1760661229000},"page":"627-640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapies and Pipeline for Hepatitis B and Hepatitis D"],"prefix":"10.1016","volume":"29","author":[{"given":"James","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishali","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Kukreja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhargav","family":"Vemulapalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Rustgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.cld.2025.06.002_bib1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1099\/jgv.0.001415","article-title":"ICTV virus taxonomy profile: hepadnaviridae","volume":"101","author":"Magnius","year":"2020","journal-title":"J Gen Virol"},{"issue":"4","key":"10.1016\/j.cld.2025.06.002_bib2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/hep.1840030408","article-title":"Ground squirrel hepatitis virus infection","volume":"3","author":"Marion","year":"1983","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.cld.2025.06.002_bib3","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S1473-3099(02)00458-9","article-title":"Baruch Blumberg\u2014Hepatitis B and beyond","volume":"2","author":"Das","year":"2002","journal-title":"Lancet Infect Dis"},{"issue":"17","key":"10.1016\/j.cld.2025.06.002_bib4","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic hepatitis B infection: a review","volume":"319","author":"Tang","year":"2018","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.cld.2025.06.002_bib5","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.3390\/microorganisms11051140","article-title":"Vertical transmission of hepatitis B Virus-An update","volume":"11","author":"di Filippo Villa","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.cld.2025.06.002_bib6","first-page":"e00667","article-title":"Hepatitis B E antigen inhibits NF-kappaB activity by interrupting K63-Linked ubiquitination of NEMO","volume":"93","author":"Wang","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.cld.2025.06.002_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.730684","article-title":"Interplay between non-canonical NF-\u03baB signaling and hepatitis B virus infection","volume":"12","author":"Lu","year":"2021","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.cld.2025.06.002_bib8","doi-asserted-by":"crossref","first-page":"e499","DOI":"10.1111\/j.1365-2893.2011.01484.x","article-title":"The hepatitis B e antigen suppresses IL-1\u03b2-mediated NF-\u03baB activation in hepatocytes","volume":"18","author":"Wilson","year":"2011","journal-title":"J Viral Hepat"},{"issue":"9","key":"10.1016\/j.cld.2025.06.002_bib9","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1136\/gutjnl-2020-323888","article-title":"Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease","volume":"70","author":"Urban","year":"2021","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.cld.2025.06.002_bib10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3390\/v14020198","article-title":"Adaptive immune responses, immune escape and immune-mediated pathogenesis during HDV infection","volume":"14","author":"Oberhardt","year":"2022","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.cld.2025.06.002_bib11","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1053\/j.gastro.2019.02.003","article-title":"Mutations in hepatitis D virus allow it to escape detection by CD8+ T cells and evolve at the population level","volume":"156","author":"Karimzadeh","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2025.06.002_bib12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.cld.2025.06.002_bib13","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.cld.2025.06.002_bib14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.21037\/atm.2017.03.69","article-title":"Alpha-interferon treatment in hepatitis B","volume":"5","author":"Woo","year":"2017","journal-title":"Ann Transl Med"},{"issue":"6","key":"10.1016\/j.cld.2025.06.002_bib15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11096-005-1319-7","article-title":"Side effects of interferon-\u03b1 therapy","volume":"27","author":"Sleijfer","year":"2005","journal-title":"Pharm World Sci"},{"issue":"2","key":"10.1016\/j.cld.2025.06.002_bib16","first-page":"CD015536","article-title":"Entecavir for children and adults with chronic hepatitis B","volume":"2023","author":"Wu","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.cld.2025.06.002_bib17","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jhep.2019.02.006","article-title":"Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients","volume":"70","author":"Park","year":"2019","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2025.06.002_bib18","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2025.06.002_bib19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41392-021-00859-y","article-title":"Ionizable liposomal siRNA therapeutics enables potent and persistent treatment of hepatitis B","volume":"7","author":"Huang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"10.1016\/j.cld.2025.06.002_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00722-23","article-title":"Novel non-HAP class A HBV capsid assembly modulators have distinct in vitro and in vivo profiles","volume":"97","author":"Vanrusselt","year":"2023","journal-title":"J Virol"},{"issue":"23","key":"10.1016\/j.cld.2025.06.002_bib21","doi-asserted-by":"crossref","first-page":"21126","DOI":"10.1021\/acs.jmedchem.4c01814","article-title":"The discovery and preclinical profile of ALG-000184, a prodrug of the potent hepatitis B virus capsid assembly modulator ALG-001075","volume":"67","author":"Vendeville","year":"2024","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.cld.2025.06.002_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156667","article-title":"Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection","volume":"11","author":"Al-Mahtab","year":"2016","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/j.cld.2025.06.002_bib23","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and safety of bepirovirsen in chronic hepatitis B infection","volume":"387","author":"Yuen","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cld.2025.06.002_bib25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1089\/nat.2021.0075","article-title":"CRISPR\/cas and hepatitis B therapy: technological advances and practical barriers","volume":"32","author":"Kostyushev","year":"2022","journal-title":"Nucleic Acid Therapeut"},{"key":"10.1016\/j.cld.2025.06.002_bib26","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion\u2019","volume":"19","author":"Blank","year":"2019","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.cld.2025.06.002_bib27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni.2039","article-title":"Immunological mechanisms of vaccination","volume":"12","author":"Pulendran","year":"2011","journal-title":"Nat Immunol"},{"issue":"3","key":"10.1016\/j.cld.2025.06.002_bib28","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jhep.2016.05.016","article-title":"Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B","volume":"65","author":"Lok","year":"2016","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2025.06.002_bib29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2017.10.027","article-title":"Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B","volume":"68","author":"Janssen","year":"2018","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2025.06.002_bib30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jhep.2022.09.027","article-title":"Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression","volume":"78","author":"Gane","year":"2022","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2025.06.002_bib31","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jhep.2023.07.003","article-title":"Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice","volume":"79","author":"Lempp","year":"2023","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2025.06.002_bib32","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jhep.2023.08.002","article-title":"Development of a highly potent anti-HBs monoclonal antibody for HBV and HDV therapy: an improvement with unsettled questions","volume":"79","author":"Mouzannar","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.002_bib33","first-page":"4107","article-title":"IMMUNIB trial (AIO-HEP-0218\/ass): a single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination withlenvatinib in advanced-stage hepatocellular carcinoma (HCC)","volume":"40","author":"Vogel","year":"2022","journal-title":"J Clin Orthod"},{"author":"Mayers","key":"10.1016\/j.cld.2025.06.002_bib34"},{"key":"10.1016\/j.cld.2025.06.002_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104995","article-title":"Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: a meta-analysis","volume":"185","author":"Abdrakhman","year":"2021","journal-title":"Antiviral Res"},{"issue":"1","key":"10.1016\/j.cld.2025.06.002_bib36","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A phase 3, randomized trial of bulevirtide in chronic hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.cld.2025.06.002_bib37","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/hep.32259","article-title":"A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic Delta hepatitis","volume":"75","author":"Yurdaydin","year":"2021","journal-title":"Hepatology"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108932612500042X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108932612500042X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:26:38Z","timestamp":1760855198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108932612500042X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S108932612500042X"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2025.06.002","relation":{},"ISSN":["1089-3261"],"issn-type":[{"type":"print","value":"1089-3261"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapies and Pipeline for Hepatitis B and Hepatitis D","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2025.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}